Evidence map›Paper›PMID 27941021›Full record

ArticleThe Journal of biological chemistry2017

Phospholipase Cγ1 (PLCγ1) Controls Osteoclast Numbers via Colony-stimulating Factor 1 (CSF-1)-dependent Diacylglycerol/β-Catenin/CyclinD1 Pathway.

Zhengfeng Yang, Seokho Kim, Sahil Mahajan, Ali Zamani, Roberta Faccio

Open access · hybridAbstract read
In one paragraph

Article in The Journal of biological chemistry, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
0.5field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 17 citations in OpenAlex.

  1. Phospholipases: Where Do We Stand?Methods in molecular biology (Clifton, N.J.) · 2027
    Review
  2. Article
  3. Article
  4. Article
  5. Review
  6. Role and Regulation of Transcription Factors in Osteoclastogenesis.International journal of molecular sciences · 2023
    Review
  7. Article
  8. Review
  9. Review
  10. Review
  11. Article
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Zhengfeng YangFrom the Department of Orthopaedics, Washington University School of Medicine, St. Louis, Missouri 63110.
Seokho KimFrom the Department of Orthopaedics, Washington University School of Medicine, St. Louis, Missouri 63110.
Sahil MahajanFrom the Department of Orthopaedics, Washington University School of Medicine, St. Louis, Missouri 63110.
Ali ZamaniFrom the Department of Orthopaedics, Washington University School of Medicine, St. Louis, Missouri 63110.
Roberta FaccioFrom the Department of Orthopaedics, Washington University School of Medicine, St. Louis, Missouri 63110 faccior@wustl.edu.
Washington University in St. Louis · US

Funding

Regulatory Pathways in Osteoclasts and Immune Cells during Inflammatory ArthritisR01AR053628 · NIAMS · WASHINGTON UNIVERSITY · PI FACCIO, ROBERTA · 2006 to 2015
$3.2M
Novel Regulators of Inflammatory Arthritis and Bone ErosionR01AR066551 · NIAMS · WASHINGTON UNIVERSITY · PI FACCIO, ROBERTA · 2015 to 2020
$2.0M
NIAMS NIH HHS R01 AR053628NIAMS NIH HHS R01 AR066551
6 · The paper itself

Abstract

Phospholipases Cγ (PLCγ) 1 and 2 are a class of highly homologous enzymes modulating a variety of cellular pathways through production of inositol 1,4,5-trisphosphate and diacylglycerol (DAG). Our previous studies demonstrated the importance of PLCγ2 in osteoclast (OC) differentiation by modulating inositol 1,4,5-trisphosphate-mediated calcium oscillations and the up-regulation of the transcription factor NFATc1. Surprisingly, despite being expressed throughout osteoclastogenesis, PLCγ1 did not compensate for PLCγ2 deficiency. Because both isoforms are activated during osteoclastogenesis, it is plausible that PLCγ1 modulates OC development independently of PLCγ2. Here, we utilized PLCγ1-specific shRNAs to delete PLCγ1 in OC precursors derived from wild type (WT) mice. Differently from PLCγ2, we found that PLCγ1 shRNA significantly suppresses OC differentiation by limiting colony-stimulating factor 1 (CSF-1)-dependent proliferation and β-catenin/cyclinD1 levels. Confirming the specificity toward CSF-1 signaling, PLCγ1 is recruited to the CSF-1 receptor following exposure to the cytokine. To understand how PLCγ1 controls cell proliferation, we turned to its downstream effector, DAG. By utilizing cells lacking the DAG kinase ζ, which have increased DAG levels, we demonstrate that DAG modulates CSF-1-dependent proliferation and β-catenin/cyclinD1 levels in OC precursors. Most importantly, the proliferation and osteoclastogenesis defects observed in the absence of PLCγ1 are normalized in PLCγ1/DAG kinase ζ double null cells. Taken together, our study shows that PLCγ1 controls OC numbers via a CSF-1-dependent DAG/β-catenin/cyclinD1 pathway.

Indexed as

Animalsbeta CateninCell ProliferationCells, CulturedCyclin D1Diacylglycerol KinaseDiglyceridesGene Knockdown TechniquesMacrophage Colony-Stimulating FactorMiceOsteoclastsPhospholipase C gammaSignal Transductionbeta CateninCcnd1 protein, mouseCyclin D1Diacylglycerol KinaseDiglyceridesMacrophage Colony-Stimulating FactorPhospholipase C gammaPlcg1 protein, mousediacylglycerolmacrophageosteoclastphospholipase Cβ-catenin (B-catenin)

Identifiers

PMID27941021
PMCPMC5270464
OpenAlexW2560477869

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.